These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21900915)

  • 1. Paraoxonase-1 and clopidogrel efficacy.
    Camps J; Joven J; Mackness B; Mackness M; Tawfik D; Draganov D; Costa LG; Paragh G; Seres I; Horke S; James R; Hernández A; Reddy S; Shih D; Navab M; Rochu D; Aviram M
    Nat Med; 2011 Sep; 17(9):1041-2; author reply 1042-4. PubMed ID: 21900915
    [No Abstract]   [Full Text] [Related]  

  • 2. Paraoxonase-1 and clopidogrel efficacy.
    Cuisset T; Morange PE; Quilici J; Bonnet JL; Gachet C; Alessi MC
    Nat Med; 2011 Sep; 17(9):1039; author reply 1042-4. PubMed ID: 21900913
    [No Abstract]   [Full Text] [Related]  

  • 3. Paraoxonase-1 and clopidogrel efficacy.
    Dansette PM; Rosi J; Bertho G; Mansuy D
    Nat Med; 2011 Sep; 17(9):1040-1; author reply 1042-4. PubMed ID: 21900914
    [No Abstract]   [Full Text] [Related]  

  • 4. Paraoxonase-1 is a major determinant of clopidogrel efficacy.
    Bouman HJ; Schömig E; van Werkum JW; Velder J; Hackeng CM; Hirschhäuser C; Waldmann C; Schmalz HG; ten Berg JM; Taubert D
    Nat Med; 2011 Jan; 17(1):110-6. PubMed ID: 21170047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catapulting clopidogrel pharmacogenomics forward.
    Topol EJ; Schork NJ
    Nat Med; 2011 Jan; 17(1):40-1. PubMed ID: 21217678
    [No Abstract]   [Full Text] [Related]  

  • 7. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
    Asano T; Kobayashi Y; Fukushima K; Iwata Y; Kitahara H; Ishio N; Kuroda N; Komuro I
    Circ J; 2008 Oct; 72(10):1707-8. PubMed ID: 18762704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of paraoxonase-1 in CYP2C19 loss-of-function carriers.
    Daali Y; Reny JL; Fontana P
    Thromb Res; 2014 Mar; 133(3):519. PubMed ID: 24439677
    [No Abstract]   [Full Text] [Related]  

  • 10. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
    Moussa I; Oetgen M; Roubin G; Colombo A; Wang X; Iyer S; Maida R; Collins M; Kreps E; Moses JW
    Circulation; 1999 May; 99(18):2364-6. PubMed ID: 10318654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of on-clopidogrel high platelet reactivity.
    Campo G; Miccoli M; Tebaldi M; Marchesini J; Fileti L; Monti M; Valgimigli M; Ferrari R
    Platelets; 2011; 22(6):399-407. PubMed ID: 21627411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting.
    Chau TN; Yim KF; Mok NS; Chan WK; Leung VK; Leung MF; Lai ST
    Hong Kong Med J; 2005 Oct; 11(5):414-6. PubMed ID: 16219965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behind the paper: stepping up to the antiplatelet.
    Dolgin E
    Nat Med; 2011 Jan; 17(1):42. PubMed ID: 21217679
    [No Abstract]   [Full Text] [Related]  

  • 15. [Genetic factors influencing efficacy of clopidogrel treatment].
    Karaźniewicz-Łada M; Danielak D; Główka F
    Kardiol Pol; 2012; 70(11):1177-81. PubMed ID: 23180531
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.
    Dangas G; Mehran R; Abizaid AS; Curry BH; Lansky AJ; Kent KM; Pichard AD; Satler LF; Paliou M; Stone GW; Leon MB
    Am J Cardiol; 2001 Feb; 87(4):470-2, A7. PubMed ID: 11179539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins do not affect platelet inhibition with clopidogrel during coronary stenting.
    Serebruany VL; Malinin AI; Callahan KP; Gurbel PA; Steinhubl SR
    Atherosclerosis; 2001 Nov; 159(1):239-41. PubMed ID: 11689228
    [No Abstract]   [Full Text] [Related]  

  • 18. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
    Martínez-Quintana E; Medina-Gil JM; Rodríguez-González F; Garay-Sánchez P; Limiñana JM; Saavedra P; Tugores A
    J Clin Pharmacol; 2014 Aug; 54(8):843-9. PubMed ID: 24504666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.
    Fefer P; Matetzky S
    Thromb Haemost; 2011 Aug; 106(2):203-10. PubMed ID: 21792462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.